Ad
related to: hepatocyte growth factor cvgxchreceptor treatment
Search results
Results from the WOW.Com Content Network
Hepatocyte growth factor (HGF) or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells , but also acts on haemopoietic progenitor cells and T cells .
Human hepatocyte growth factor (HGF) is an 80kD [1] pleiotropic protein that is endogenously produced by a variety of cell types from the mesenchymal cell lineage (such as cardiomyocytes and neurons). [4] It is produced and proteolytically cleaved to its active state in response to cellular injury or during apoptosis.
Hepatocyte growth factor receptor (HGF receptor) [5] [6] is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. [7] The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers. [1] Many c-Met inhibitors are currently [when?] in clinical trials.
Cabozantinib was granted orphan drug status by the US Food and Drug Administration (FDA) in November 2010, [20] and in February 2017. [21]Exelixis filed a new drug application with the FDA in 2012, [22] and in November 2012, cabozantinib in its capsule formulation was granted marketing approval by the FDA under the name Cometriq for treating people with medullary thyroid cancer.
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers. [1] It is a humanized monoclonal antibody that binds to hepatocyte growth factor, thus inhibiting the c-MET receptor signaling cascade. [2] Ficlatuzumab was developed by AVEO Pharmaceuticals.
The regulatory mechanisms prepare hepatocytes to enter the cell cycle. The proliferation phase involves activation of various growth factors, including two factors that play a major role in liver regeneration, EGFR (epidermal growth factor receptor) and c-Met. During this phase, hepatocytes undergo a series of cell division cycles and expansion ...
Cabozantinib, which is an inhibitor of multiple tyrosine kinases including VEGFR, hepatocyte growth factor receptor (MET) and AXL and ramucirumab, an antibody directed against VEGF receptor 2, are second line therapies which have been shown to reduce the risk of death compared to placebo. [6] [79] [80]
Ad
related to: hepatocyte growth factor cvgxchreceptor treatment